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1. Introduction  
KRAS is an important oncogene that participates in the mitogen-activated protein kinase 
(MAPK) pathway. The MAPK pathway is involved in various cellular functions, including 
cell proliferation, differentiation and migration. Mutations in KRAS are found in many 
types of malignancies including lung cancer (Fong et al., 1998; Slebos & Rodenhuis, 1989; 
Chen et al., 2003; Siegfried et al., 1997), colorectal cancer (Calistri et al., 2006; Weijenberg et 
al., 2008; Wang et al., 2007), and pancreatic cancer (Smit et al., 1988; Gocke et al., 1997). As 
early as 1989, Slebos et al. have identified that the KRAS mutation status can be used for 
lung cancer detection or prognosis prediction (Slebos & Rodenhuis, 1989). In 1995, 
Yakubovskaya et al. detected 12 different KRAS mutations in nearly 60% of tissue specimens 
of non-small cell lung cancer (NSCLC) patients (Yakubovskaya et al., 1995). As for 
pancreatic, stomach and breast cancers, there have been a number of studies reporting 
KRAS mutations (Smit et al., 1988; Gocke et al., 1997; Deramaudt & Rustgi, 2005; Carstens et 
al., 1988; Lee et al., 2003; Shen et al., 2008). The predictive value of KRAS mutation in 
metastatic colorectal cancer patients treated with cetuximab plus chemotherapy has recently 
been shown in that patients with tumor KRAS mutation were resistant to cetuximab and 
had shorter progression survival and overall survival times compared with patients without 
mutation (Lievre et al., 2006; Lievre et al., 2008). Additionally, NCCNClinical Practice 
Guidelines in Oncology Version 3, 2008, strongly recommends KRAS genotyping of tumor 
tissue (either primary tumor or metastasis) in all patients with metastatic colorectal cancer 
before treatment with epidermal growth factor receptor (EGFR) inhibitors. KRAS mutational 
analysis has advantages over attempts to predict responsiveness to anti-EGFR antibodies.  
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To date, detection of KRAS mutations are limited to traditional techniques. The traditional 
techniques such as direct sequencing, polymerase chain reaction and restriction fragment 
length polymorphism are complicated and can easily be used only in tissue samples, which 
limits KRAS mutation detection in clinical applications. In order to improve the mutant 
KRAS detection efficiency, we successfully developed an Activating KRAS Detection Chip 
and colorimetric membrane array (CLMA) technique capable of detecting KRAS mutation 
status by screening circulating carcinoma cells in the surrounding bloodstream (Chen et al., 
2005; Wang et al., 2006; Chong et al., 2007; Yang et al., 2009; Yen et al., 2009; Yang et al., 
2010). However, the sensitivity still needs further improvement. In addition, the digoxigenin 
enzyme used on the colorimetric gene chip platform is too costly for routine laboratory 
diagnosis, and the high criteria of the operation techniques have prevented its widespread 
availability for clinical applications. Therefore, we have developed the next generation gene 
chip operation platform named the weighted enzymatic chip array (WEnCA), as shown in 
figure 1. The technical difference between the WEnCA and CLMA system includes the 
different weighted value for each gene target on the gene chip of the WEnCA system, 
dependent on the importance of each gene during the cancer development process. 
Furthermore, the conventional digoxigenin system was replaced by the biotin-avidin 
enzyme system to lower the cost. The manual operation process of the WEnCA system has 
been successful established and published (Tsao et al., 2010; Yen et al., 2010). The proposed 
platform may benefit post-operative patients or facilitate patient follow-ups, and also bring 
breakthrough improvements in the prediction and evaluation of the therapeutic effects of 
anti-EFGR drugs. However, as the technical threshold of chip array remained relatively 
high, human errors during clinical examinations were commonly seen, and the propagation 
of associating operations somehow became restricted. 
The analysis of gene overexpression has led to fundamental progress and clinical advances 
in the diagnosis of disease (Chen et al., 2005; Wang et al., 2006). The techniques that are 
commonly used to study gene overexpression include Northern blot, reverse transcriptase 
polymerase chain reaction (RT-PCR), and real-time PCR (Chong et al., 2007; Yen et al., 2009; 
Yanget al., 2009). Since Northern blot involves complex steps and a large numbers of 
samples, its application is limited to research instead of clinical diagnosis. On the other 
hand, since RT-PCR and real-time PCR are performed through a series of simple steps, they 
are applied extensively for the detection of a single gene, as with the hepatitis virus and 
infectious pathogens (Yang et al., 2010; Tsao et al., 2010). Although the invention of PCR 
ranks as one of the greatest discoveries of all time, most PCR techniques have a few 
common problems: (1) contamination, i.e., false positive results from oversensitive detection 
of, say, aerosolized DNA or previous sample carry-over; (2) RT-PCR is regarded as only 
semi-quantitative, since it is difficult to control the efficiency of sequence amplification 
when comparing different samples; and (3) interference is caused by annealing between the 
primers. RT-PCR or real-time PCR is used extensively in the detection of a single-gene target 
(Yen et al., 2010; Harder et al., 2009; Sheu et al., 2006). For the detection of multiple targets or 
gene clusters, PCR-related techniques tend to have the disadvantages of being time-
consuming, cumbersome and costly. 
The rapid development of biotechnology in recent years has made gene chips an important 
tool in clinical diagnosis or drug efficacy evaluation (Popovtzer et al., 2008). Our previous 
study has developed and evaluated a membrane array-based method for simultaneously 
detecting the expression levels of multiple mRNA markers from circulating cancer cells in 
the peripheral blood for cancer diagnosis (Chen et al., 2006). In those studies, the expression 
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levels of molecular markers were simultaneously evaluated by RT-PCR and membrane 
array. Data obtained from RT-PCR and membrane array were subjected to linear regression 
analysis, revealing a high degree of correlation between the results of these two methods 
(r=0.979, P<0.0001) (Chen et al., 2006). However, even though the array-based chip 
technology has proven to be a powerful platform for gene overexpression analysis, some 
drawbacks still exists and may hinder its practical applications. Two of the critical issues are 
its tedious sample pretreatment and time-consuming hybridization process. Sample 
pretreatment process including cell lysis, DNA/RNA extraction and several tedious 
washing process requiring well-trained personnel and specific instruments, which indicate 
that the array methods can be only operated in a central lab or medical center, and also 
limited its applicability for clinical diagnosis. Besides, the manual operation may cause the 
fragile RNA samples to be degraded by the surrounding RNases (Chirgwin et al., 1979; 
Chomczynski, 1993). Recently, magnetic bead-based extraction has been widely employed 
for high-quality RNA extraction. When compared with the conventional methods, the high-
quality RNA samples can be stably extracted by simply applying an external magnetic field. 
Regarding to the hybridization process, it is another time-consuming process due to slow 
diffusion between target and immobilized probes for conventional array technology. It has 
been reported that proper mixing is important to achieve an efficient hybridization 
(Southern et al., 1999). The rotation of the array was reported to be effective in reduction of 
hybridization time (Chee et al., 1996). Regarding to the above-mentioned issues, there is a 
great need to develop a rapid and automatic sample pretreatment platform to isolate 
specific RNA samples from cells and efficient hybridization for array-based methods. 
With the rapid advancements in the field of fluid manipulation technology, and especially 
biomedicine development in recent years, automated and rapid biomedical analysis is now 
considered to offer the greatest potential and market value (Chen et al., 2003; Siegfried et al., 
1997). In terms of biomedical applications, the automatic biomedical analysis system that 
integrated of several fluid manipulation device including transportation, mixing and 
heating, which based on the “Lab-on-a-chip” concept, has the advantages of high detection 
sensitivity, portability, low sample/test sample consumption, low power consumption, 
compact size, and low cost. Compared to the conventional analysis techniques, it represents 
a significant breakthrough. With a variety of innovative techniques, a wide range of 
precision fluid manipulation devices have been integrated to control biological fluids such 
as whole blood, reagents and buffers, to reduce the size of the biochemical analytical 
instruments, and integrate the processes into a one-step automated system that facilitates 
the rapid conducting of biomedical analysis from samples to results (Calistri et al., 2006). In 
this research, the integrated fluid manipulation technology is adopted to operate the 
WEnCA platform (figure 1), significantly reduce detection time and errors arising from 
human operation. Thus, the bottleneck that was preventing the commercialization of the 
chip detection technique has been overcome. In the current study, we developed an 
automatic gene chip analyzer which named Chipball (as shown in Fig. 3b), and we have 
introduced an automatic WEnCA operating platform to improve the manual operations. 
The system is designated the ‘WEnCA-Chipball system’, as shown in figure 2. In order to 
understand the difference between test results obtained by operating the WEnCA-Chipball 
and WEnCA-manual systems, and to assess the clinical applications of the WEnCA-Chipball 
system a number of screenings were evaluated. The WEnCA-Chipball platform can be 
automatically operated to effectively reduce the manual errors and limitations due to 
current technical criteria. 
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Fig. 1. The manual operation platform of Weighted Enzymatic Chip array (WEnCA) 
(Hsiung, et al., 2009). 
 
 
Fig. 2. The automatic WEnCA-Chipball operation platform (Hsiung, et al., 2009). 
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In addition, the activated KRAS expression in blood samples of 209 lung cancer patients was 
determined according to the experimental procedure shown in Figure 3 and then analyzed 
by both WEnCA-manual and WEnCA-Chipball; the results were compared and the clinical 
applicability of WEnCA-Chipball was defined. Further comparisons were performed on the 
sensitivity, the specificity and the accuracy of the WEnCA-manual and WEnCA-Chipball; 
the application, the operation time, and the cost of the two platforms were investigated to 
evaluate the clinical applicability potential of WEnCA-Chipball. 
  
(a) 
 
(b) 
Fig. 3. (a) The research flow chart of current study (Hsiung, et al., 2009). (b) Photograph of 
the proposed automatic gene chip analyzer. 
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2. Materials and methods 
2.1 Specimens collection 
Initially, cancer tissues from two hundreds selected cancer patients including 85 patients 
with breast cancer, 64 patients with colorectal cancer (CRC), and 51 patients with non-small 
cell lung cancer (NSCLC) cancer who had undergone surgical resection or biopsy between 
January 2007 and December 2008 were enrolled into this study. The data from the 200 
cancerous patients were used for the analysis of sensitivity, specificity and diagnostic 
accuracy of WEnCA-Chipball. Tissue samples from various cancer patients were divided into 
two groups, one group of 100 cancer tissues with KRAS mutation including 32 CRCs, 51 
breast cancers and 17 NSCLCs and the other group of 100 cancer tissues without KRAS 
mutation including 32 CRCs, 34 breast cancers and 34 NSCLCs were used to determine the 
cut-off-value of weighted enzymatic chip array method for further circulating tumor cells 
(CTCs) analysis of 209 lung cancer patients. In order to clinically evaluate and compare both 
two systems, CLMA and WEnCA-Chipball; blood specimens were collected within test 
tubes containing anticoagulant sodium citrate from 209 lung cancer patients. To avoid 
contamination of skin cells, the blood sample was taken via an intravenous catheter, plus the 
first few milliliters of blood were discarded. Total RNA was immediately extracted from the 
peripheral whole blood, and then served as a template for cDNA synthesis. Sample 
acquisition and subsequent usage were approved by the Institutional Review Boards of 
three hospitals. Written informed consent was obtained from all participants.  
2.2 Total RNA isolation and cDNA synthesis 
Total RNA was isolated from the collected cancer tissue specimens using the acid –
quanidium-phenol-chloroform (AGPC) method according to the standard protocol. The 
RNA concentration was determined spectrophotometrically based on the absorbance at 260 
nm. First-strand cDNA was synthesized from total RNA using the Advantage RT-PCR kit 
(Promega, Madison, WI) and then reverse transcription was performed in a reaction mixture 
consisting of Transcription Optimized Buffer, 25 mg=mL Oligo (dT)15, Primer, 100mM=L 
PCR Nucleotide Mix, 200 mM=L MLV Reverse Transcriptase, and 25 mL Recombinant 
RNasin Ribonuclease Inhibitor. The reaction mixtures were incubated at 42ºC for 2 h, heated 
to 95ºC for 5 min, and then stored at 48ºC until the analysis. 
2.3 Establishment of membrane array-based method 
The rapid development of biotechnology in recent years has made gene chips an important 
tool in clinical diagnosis or drug efficacy assessment (Popovtzer et al., 2008). Visual OMP3 
(Oligonucleotide Modeling Platform, DNA Software, Ann Arbor, MN) was used to design 
probes for each target gene and β-actin, the latter of which was used as an internal control. 
The probe selection criteria included strong mismatch discrimination, minimal or no 
secondary structure, signal strength at the assay temperature, and lack of cross-
hybridization. The oligonucleotide probes were then synthesized according to the designed 
sequences, purified, and controlled before being grafted onto the substracts. The newly 
synthesized oligonucleotide fragments were dissolved in distilled water to a concentration 
of 20 mM, applied to a BioJet Plus 3000 nL dispensing system (BioDot, Irvine, CA), which 
blotted the selected target oligonucleotides and TB (Mycobacterium tuberculosis) and the β-
actin control sequentially (0.05 µL per spot and 1.5 mm between spots) on SuPerCharge 
nylon membrane (Schleicher and Schuell, Dassel, Germany) in triplicate. Dimethyl sulfoxide 
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(DMSO) was also dispensed onto the membrane as a blank control. In addition, the 
housekeeping gene was β-actin while the bacterial gene was derived from Mycobacterium 
tuberculosis. Both served as positive and negative controls, respectively, and blotted on the 
membrane. After rapid drying and cross-linking procedures, the preparation of membrane 
array for target genes expression was accomplished. Our previous study developed and 
evaluated a membrane array-based method simultaneously detecting the expression levels 
of multiple mRNA markers from circulating cancer cells in peripheral blood for cancer 
diagnosis (Wang et al., 2006; Yen et al., 2009; Tsao et al., 2010). We have carried out 
membrane array analysis using normal human adrenal cortical cells with KRAS mutation, 
and obtained 22 upregulated genes most closely related to the KRAS oncogene through 
bioinformatic analysis. The Activating KRAS Detection Chip for detecting the activated 
KRAS from peripheral blood was successfully constructed. Although this method is a 
convenient way of directly using peripheral blood for detecting KRAS activation, and has 
achieved major breakthroughs in clinical applications, the sensitivity of this technique is 
only about 84% (Chen et al., 2005).  
The colorimetric membrane array (CLMA) was reported in clinical applications for 
diagnosis of cancer (Harder et al., 2009; Sheu et al., 2006). By the CLMA method, the 
interpretation importance of each gene is equally included in the diagnosis and each gene is 
calculated by the same value; this does not evaluate or differentiate the importance of each 
gene for specific disease diagnosis. That is a major limitation of this technique in clinical 
application (Tsao et al., 2010). In addition, the cost of the digoxigenin enzyme used on the 
CLMA platform was too high for routine laboratory diagnosis, and the high criteria of the 
operation techniques prevented its widespread availability for clinical applications. 
Therefore, as mentioned above, our team developed a new generation gene chip operation 
platform designated as WEnCA. The technical difference between the WEnCA system and 
the conventional membrane array includes the different weighted value for each gene target 
on the gene chip, dependent on the importance of each gene during the carcinogenesis of 
cancer. Furthermore, the conventional digoxigenin system was replaced by the biotin-avidin 
enzyme system to lower costs.  
2.4 Configuration of integrated automatic gene chip analyzer 
In order to realize the concept of automatic performing the gene chip operation procedure 
from samples to images, an integration system composed of several modules including fluid 
manipulation, temperature controlling, magnetic controlling, actuation, image acquiring 
and operation platform was investigated, which can perform the critical procedure of array-
based gene chip operation such as sample pretreatment, DNA/mRNA purification, reverse 
transcription, probe labeling and hybridization process, and the image of the gene chip can 
be acquired automatically after the hybridization as well. The framework of the proposed 
automatic gene chip analyzer was shown in Fig. 4. Regarding to the Lab-on-chip concept, 
we have designed an operation platform to provide the interaction fields of the fluid such as 
samples and reagents, and gene chip operation. The operation platform also was considered 
as an interface between the sample/reagents and instrument, so that the fluid can be 
manipulated by utilizing the external devices. In addition, a vessel device contains 
corresponding reagents to specific process was included in the system. Briefly, the major 
functions of the proposed system were samples/reagents manipulation, cell lysis, mRNA 
collection/purification, reverse transcription, probe labeling, and gene chip hybridization. 
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The images of gene expression can be acquired accordingly. As mentioned above, several 
modules were designed to achieve these functions. For sample/reagents transporting, 
samples and reagents can be manipulated and transported through the micro piezoelectric 
pump device, the volume can be controlled precisely and the operation process can be 
performed in sequence. By utilizing the fluid manipulation device, the reagents can be 
sucked and transported from the vessel to the operation platform in specific area, and the 
reactants can be manipulated between the reaction chambers, the wasted fluid also can be 
excluded from the operation platform accordingly. Since the temperature control is the 
critical issue for the gene chip operation, the temperature of each operation process such as 
cell lysis and hybridization can also be controlled by embedded heaters and thermal 
sensors, the temperatures, heating/cooling rates and thermal distribution can be well 
controlled. Compare to the time-consuming and instrument-intensive conventional method 
of mRNA purification, the commercial magnetic beads were utilized to realize the automatic 
mRNA purification in this system, and a magnetic controlling device was designed for the 
magnetic beads manipulation, so that the mRNA can be collected accordingly. Furthermore, 
for the purpose of interaction enhancing, an active mixing device for shaking mechanism 
was added into the system. By utilizing the simplified design, the operation platform can be 
rotated to generate the mixing effect of the samples and reagents inside the operation 
platform. Finally, the images of the gene chip representing the gene expression can be 
obtained after all the operation process, and the images can be recorded by the image 
acquiring device, which including the CCD (Charged-couple device) and image analysis 
software. The image data can be stored and transmitted to the central laboratory via 
internet. 
 
 
Fig. 4. The framework of the proposed automatic gene chip analyzer. 
2.5 Design of the operation platform 
In this study, for the purpose to provide the interface between sample/reagents and 
modules which can control the critical parameters of each process, an operation platform 
has been designed to perform the sample manipulation and gene analysis. For easy 
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fabrication and low cost, the material utilized for the operation platform was 
Polymethylmethacrylate (PMMA), the width and length of the substrate was 10 cm each, 
and the thickness was 1 cm. As shown in Fig. 5, we have divided the platform into four 
chambers for specific operation process, including sample pretreatment area, sample 
purification area, transcription and probe labeling area, and hybridization area. The four 
areas were fabricated by a micro-milling machine, the diameter and depth of each chamber 
has been calculated precisely to ensure the volume was sufficient for each process. Initially, 
a membrane array device with specific gene probes was first integrated into the 
hybridization area, and then the operation platform was placed onto a telescopic loading 
tray structure, which was designed in this system for the orientation and operation of the 
platform with external controlling device. Each area on the platform was corresponding to 
an external module for its specific operation process. For instance, a temperature controlling 
device embedded onto the tray structure including a set of heater and thermal sensor was 
placed underneath the sample pretreatment area for cell lysis application. We have set up 
three temperature controlling device corresponding to area I, III and IV for the adjustment 
of operation temperature, and a simple design of magnet lift-up mechanism to control the 
magnetic force and collect the magnetic beads in area II for mRNA purifying application. In 
order to transport the reagents into the operation chamber and manipulate the 
sample/reagents between the chambers, several commercial piezoelectric pumps were 
utilized. Sets of sucking needles were inserted into the reagent vessels and operation 
chamber before the piezoelectric pumps were activated, and corresponding 
samples/reagents can be transported to the specific chamber by activating specific pump. 
After the samples/reagents transportation in each chamber, a mixing mechanism was 
required for the sample interactions. The tray structure and operation platform can be 
clockwise rotated simultaneously by utilizing a cam and electric motor device. The rotation 
speed can be adjusted within a dynamic range from 50 to 200 rpm. As shown in fig. 5, the 
  
 
Fig. 5. Illustration of the fluidic operation platform, which divided into four areas, the 
blood/specimen can be operated sequentially through the four operation process. The 
membrane array device was firstly integrated into the hybridization area, and then the 
operation platform was placed onto the telescopic loading tray for further external control.  
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image of the gene expression on the gene chip can be obtained after finished all operation 
process. The darkness of each probe can reveal the interaction between pretreated 
DNA/RNA sample and probe with specific sequence on gene chip. The image can be 
recorded by a CCD, and then the recorded image can be sent to the commercial image 
analysis software for further analysis. The darkness of each probe can reveal the expression 
of specific sequence for the gene information analysis.  
2.6 Operating procedure of automatic gene chip analyzer 
Firstly, a sample pretreatment process from whole blood to mRNA was required, as shown 
in Fig. 6. In order to breakdown the sample cells and isolate mRNA from the specimen, the 
fluid manipulation device delivers the whole blood and lysis buffer to the first reaction 
chamber (sample pretreatment area), as shown in Fig. 6(a). The fluid manipulation device 
also delivered the magnetic beads, binding buffer, and washing buffer from reagent vessel 
to the first reaction chamber (Fig. 6b). The samples were then mixed by the active mixing 
device to ensure that the samples react effectively and to enhance the mRNA conjugation 
with the magnetic beads. As shown in Fig. 6(c), biotin poly dT and streptavidin magnetic 
beads were used to isolate the mRNA. The reacted samples and the beads that have 
conjugated mRNA onto the surface can then be delivered to the second reaction chamber 
(sample purification area) by the fluid manipulation device. In this area, magnetic 
controlling device was utilized to manipulate magnetic beads and to separate the target 
mRNA samples from the surroundings (Fig. 6d). The mRNA-conjugated magnetic beads can 
be collected by the external magnet and then washing buffer can be transported into the 
area by the fluid manipulation device for further washing process (as Fig. 6e). The 
remaining waste fluid excluding the mRNA-conjugated beads can be transported by the 
fluid manipulation device to the waste collection area. The elution buffer was then delivered 
through the fluid manipulation device to the reaction chamber for the further mixing 
reaction. The mRNA-conjugated magnetic beads were demagnetized and suspended in the 
elution buffer after the external magnet descended. As shown in Fig. 6(f), after the mixing 
and elution process, the magnet activated again to separate the beads and target mRNA 
samples. Hence the buffer contained the purified mRNA samples that have been extracted 
and released were then delivered through the fluid manipulation device to the third 
reaction chamber (transcription and probe labeling area). The required temperature for the 
transcription can be regulated by the temperature controlling device allowing the mRNA to 
be converted into stable cDNA for chromogen labeling for the bio-molecular test target. The 
reacted samples and buffer solution were then delivered by the fluid manipulation device to 
the hybridization area for the hybridization process. Meanwhile, prior to deliver the 
samples to the hybridization area, the gene chip was placed in the hybridization area for the 
pre-hybridization procedure. The labeled cDNA samples then entered the reaction chamber 
contained the Express Hyb hybridization solution where the required temperature for the 
hybridization reaction was regulated by the temperature controlling device. Subsequently, 
samples and reagents including biotin-labeling mixture, washing buffer, blocking buffer, 
strepavidin conjugation, detection buffer, DAB, and ddH2O were delivered into the chamber 
through the fluid manipulation device. Finally, after all processes of the hybridization 
reaction were completed, the image of gene chip can be obtained and acquired by the image 
acquiring device and image/information processing system for the further gene expression 
information analysis. A detailed operation process can be seen in Table 1. As the result, the 
overall operation time can be decreased less than 8 hours, which was shorten by 70% 
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Fig. 6. Illustration of the purifying and separation process from whole blood to mRNA samples.  
 
Areas     Reagents Volume (ml) Time (min) Temperature (oC) 
Lysis Solution 1.02 
Whole Blood 4 
15 
60 
Magnetic Beads 0.25 1 
Sample 
Pretreatment 
Area 
Binding Solution 0.25 4 
Washing Buffer I 0.25 3 
Washing Buffer II 0.25 3 
Sample 
Purification 
Area Elution Solution 0.25 5 
Room 
Temperature 
RT Reagents 0.25 40/5 42/75 Transcription 
and Probe 
Labeling Area  
DIG-Labeling 
solution 
0.25 60 
37 
Hybridization 
solution 
3 30 
Washing Buffer I 2 10 
42 
Washing Buffer II 2 10 
Washing Buffer III 2 10 
Blocking Buffer 2 10 
Anti-DIG AP 
Buffer 
5 10 
Detection Buffer 2 10 
Hybridization 
Area 
NBT/BCIP 1 3 
Room 
Temperature 
Table 1. Detailed operation process of the automatic gene chip analyzer. 
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when compared to the conventional manual method, and also represented the great 
potentials and advantages of the proposed automatic gene chip analyzer for gene diagnosis 
applications. 
3. Results 
3.1 Comparison between colorimetric membrane array and weighted enzymatic chip 
array method 
In order to verify the sensitivity, specificity and accuracy of the activating KRAS detection 
chip, we enrolled 209 NSCLC patients (pathologically proved) to detect the activating KRAS 
from their peripheral blood specimens. All specimens were tested by both the CLMA and 
WEnCA methods. We also analyzed tissue samples of 209 cases of patients with KRAS 
mutations by a traditional PCR-combing direct sequencing method to be a standard 
reference. Experimental results indicated that there were 71 cases with KRAS mutations by 
sequencing analysis, and a total of 59 patients tested positive by the CLMA, while the 
WEnCA tested positive in a total of 66 cases. Moreover, in 138 NSCLC cases without KRAS 
mutation, CLMA detected 133 cases as negative, and WEnCA detected 130 cases as negative. 
After statistical analysis, the CLMA sensitivity was 83%, specificity 96%; and WEnCA 
sensitivity could be raised to be 93%, while the specificity still is maintained at around 94%. 
The examinational comparison results also compared the ability of peripheral blood 
detection results of two technology platforms where 3 cancer cells /cc blood were detected 
by the WEnCA, and 5 cancer cells /cc blood by the CLMA. These findings suggest that the 
WEnCA platform has a higher detection rate for activated KRAS oncogene, and great 
potential for further investigation and clinical application. 
To determine the cutoff value of the Activating KRAS Detection Chip by the WEnCA 
method, we analyzed 200 cancer tissues of which 100 had the KRAS mutation and the others 
had wild-type KRAS. The 200 tissues collected underwent mRNA extraction and first cDNA 
labeling before reacting to the Activating KRAS Detection Chip by the WEnCA-manual 
method. After signal development, each gene spot density was normalized using the density 
of β-actin on the same chip. Next, the result obtained from the cancer tissue with KRAS 
mutation was divided by the normalized value obtained from the sample spot of the tissue 
without mutant KRAS to obtain the ratio. A ratio higher than 2 was defined as being 
positive for gene overexpression. In terms of analysis using WEnCA, to determine the 
weighted value of each gene spot, we divided the percentage of each gene overexpression in 
the 100 cancer tissues with the activating KRAS mutation to provide four classes. The gene 
spot that showed overexpression in over 80 cancer tissues had a weighted value of 4 (3 in 
70−80 cancer tissues, 2 in 60−70 cancer tissues, and 1 in 50−60 cancer tissues). After the 
reaction through WEnCA, the positive gene spots were multiplied by their respective 
weighted values to obtain the total score of the chip. Then underwent analysis using the 
receiver operating characteristic curve can be obtained with a positive reaction cutoff value 
of 20. Results showed that the sensitivity reached 96% and the specificity reached 97%. 
3.2 Detection limitation of the WEnCA-manual and WEnCA-Chipball assay  
Evaluating the detection limitation of WEnCA-manual and WEnCA-Chipball system, with 
the addition of 100, 25 and 12 cancer cells that possessed the activated mutant KRAS into 5cc 
of blood, which obtained total scores higher than the cutoff value 20 in both systems. In 
addition, when only 6 cells were added, in which case the total score equaled 8 in WEnCA-
www.intechopen.com
Clinical Application of Automatic Gene Chip Analyzer (WEnCA-Chipball)  
for Mutant KRAS Detection in Peripheral Circulating Tumor Cells of Cancer Patients   
 
163 
manual and 5 in WEnCA-Chipball system, which are both lower than 20. Therefore, no 
significant difference was found between the detection limitations of the two systems. 
3.3 Clinical assessment of the accuracy of WEnCA-manual and WEnCA-chipball 
system 
To further understand the practical clinical detection of the WEnCA-Chipball system, we 
obtained blood samples of 209 pathology-proven lung cancer patients and analyzed the 
KRAS pathway-related genes overexpression in those blood specimens by previously 
constructed Activated KRAS Detection Chip using both the WEnCA-manual and WEnCA-
Chipball systems. The paired cancer tissue with KRAS mutational status then served as the 
reference standard. As shown in Table 2, the results are as follows: 74 cases of the 209 
clinical samples were identified with activated KRAS by the WEnCA-manual method, and 
the WEnCA-Chipball system test results showed in a total of 71 cases. Among them, 66 were 
positive through WEnCA-manual and 63 through WEnCA-Chipball. Moreover, among the 
138 paired cancer tissues with wild type KRAS, 130 were negative through both WEnCA-
manual and WEnCA-Chipball system. According to the results, we can obtain the 
sensitivity, specificity and accuracy of WEnCA-manual were 93%, 94% and 94%; the 
sensitivity, specificity and accuracy of WEnCA-Chipball were 89%, 94%, and 92%, 
respectively. As the results in Table 3, using WEnCA-Chipball, the average total score of the 
positive sample was 6.1 lower and the average total score of the negative sample was 3.9 
lower while the overall average total score was 4.7 lower than the WEnCA-manual. 
Regarding to the operation time, the WEnCA-Chipball system takes 7.5 h to complete all 
tasks, while the operation time of the WEnCA-manual system is around 72 h, which was 
approximately 9 folds than the time required for the automatic system. The operating cost of 
the WEnCA-manual system was approximately 5 times more expensive than that incurred 
for the WEnCA-Chipball system. There was no difference in the detection limitation 
between the two systems. We believe that the WEnCA-Chipball operating system has 
considerable potential in clinical medicine applications. 
 
WEnCA-Chipball 
( WEnCA-manual ) 
 
Negative Positive Total 
Wild Type 130 (130) 8(8) 138 
KRAS 
Mutation 8 (5) 63(66) 71 
Total 138 (135) 71(74) 209 
Table 2. The sensitivity, specificity and accuracy of WEnCA-Chipball and WEnCA-manual 
system  
 
                         Method 
Mean score 
WEnCA-manual WEnCA-Chipball 
Difference 
(Chipball- Manual) 
Positive specimens 46.1 40 -6.1 
Negative specimens 13.8 9.9 -3.9 
Total specimens 25.2 20.6 -4.7 
Table 3. Comparing the total score of Activating KRAS Detection Chip analyzed by 
WEnCA-manual and WEnCA-Chipball system 
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4. Discussion 
In recent years, target therapy has rapidly developed. Research and development for the 
targeted therapy drugs, such as Iressa and Cetuximab, have been proven efficient in 
advanced NSCLC (Thatcher, 2007; Chang, 2008). Many studies report that KRAS mutations 
are highly-specific independent predictors of response to single-agent EGFR tyrosine kinase 
inhibitors (Iressa) in advanced NSCLC; and, similarity to anti-EGFR monoclonal antibodies 
(Cetuximab) alone (Rossi et al., 2009; Tiseo et al., 2010). However, at the present time, 
therapeutic targets such as HER2/neu, EGFR, KRAS, Raf, etc., are analyzed using RT-PCR 
combining direct sequencing, fluorescence in situ hybridization (FISH), real-time PCR, and 
other methods (Hilbe et al., 2003; Cappuzzo et al., 2007; Akkiprik et al., 2008). The above 
methods have disadvantages such as inadequate sensitivity, and the need to collect patients’ 
cancer tissues as specimens, which make medicinal effect evaluations prior to clinical 
treatment cumbersome. RT-PCR and real-time PCR are applied for the detection of single 
genes, and most PCR techniques have a few common problems: (1) contamination, such as 
false-positive results from oversensitive detection of aerosolized DNA or previous sample 
carry-over; (2) RT-PCR is regarded as only semi-quantitative, since it is difficult to control 
the efficiency of sequence amplification when comparing different samples; and, (3) 
interference is caused by annealing between the primers. RT-PCR or real-time PCR is used 
extensively in the detection of a single-gene target. For the detection of multiple targets or 
gene clusters, PCR-related techniques tend to be time-consuming, labor-intensive, and 
costly. Therefore, the current study successfully developed the WEnCA-Chipball to 
effectively address and solve those problems. 
In the WEnCA-Chipball system, the total operation time from input of samples to 
completion of the image analysis was about 7.5 h, which is a substantial decrease in time 
when compared to the three days required for the original manually operated membrane 
array, and significantly minimizes the occurrence of human errors. The WEnCA-Chipball 
system not only provides an innovative automatic system for clinical target therapy efficacy 
evaluation, but also improves the clinical usability and accuracy compared to the manual 
method. Thus, it has been proven to be a practical means to assess the drug efficacy of 
clinical target treatment. 
The WEnCA-Chipball system developed by this research team not only retains the 
advantages of the Lab-on-a-chip, but also overcomes the problem of the microfluidic chip’s 
unsuitability for continuous operation and linkage to an interpretation system. As the 
world’s first automatic chip analyzer, it will be useful in the future for the molecular 
diagnosis of infectious diseases, the detection of CTC through chip replacements, or the 
assessment of drug efficacy.  
5. Future trends 
Medical automation technology is the future trend that can reduce labor, operation errors, 
and time-consumption. WEnCA-Chipball is suited for clinical application to detect mutant 
KRAS in CTCs before target therapy. The specialized automatic gene chip detecting system 
would be designed for the fast and accurate detection of KRAS in CTCs in each human 
cancer specimen. This is the challenge to meet for the years ahead.  
The WEnCA-Chipball system, through a built-in computer system, will not only instantly 
produce the results of the chip analysis but also connect to a global network. The detection 
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results can be transmitted locally in any operation area and stations around the world 
through common software used in data transmission and interpretation. The station 
networks around the world can be completed through the prevalent WEnCA-Chipball 
system. The WEnCA-Chipball system is believed to be capable for extensive applications in 
clinical medicine, and holds great potential for future development. 
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